Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 May;57(5):512–513. doi: 10.1038/bjc.1988.116

A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).

D B Smith 1, M J Lind 1, S B Kaye 1, E S Newlands 1, G R Blackledge 1, A Gibson 1
PMCID: PMC2246396  PMID: 3395557

Abstract

Methylene dimethane sulphonate (MDMS), the first member of the homologous series of dimethane sulphonic acid esters, was administered to 19 patients with advanced epithelial ovarian cancer. All patients had received prior chemotherapy and in addition 3 had received prior radiotherapy. MDMS was given as an i.v. bolus injection at a dose of 125mg m-2 and repeated in a q35 day schedule. Ten patients received only one course, six two courses, two three courses and one four courses. The major toxicity was thrombocytopenia which was cumulative. Serious neutropenia did not occur and no infective episodes requiring i.v. antibiotics were seen. Seven patients experience hair loss and four nausea and vomiting. Sixteen patients were evaluable for response but no objective remissions were seen although three patients had stable disease lasting at least 8 weeks. MDMS is therefore not recommended for further trial in epithelial ovarian carcinoma.

Full text

PDF
512

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bedford P., Fox B. W. DNA-DNA interstrand crosslinking by dimethyanesulphonic acid esters. Correlation with cytotoxicity and antitumour activity in the Yoshida lymphosarcoma model and relationship to chain length. Biochem Pharmacol. 1983 Aug 1;32(15):2297–2301. doi: 10.1016/0006-2952(83)90176-4. [DOI] [PubMed] [Google Scholar]
  2. Fox B. W. Collateral sensitivity between methylene dimethane sulfonate and halogenated methotrexate derivatives in the Yoshida sarcoma in vivo and in vitro. J Natl Cancer Inst. 1977 Apr;58(4):955–958. doi: 10.1093/jnci/58.4.955. [DOI] [PubMed] [Google Scholar]
  3. Fox B. W. The sensitivity of a Yoshida sarcoma to methylene dimethane sulphonate. Int J Cancer. 1969 Jan 15;4(1):54–60. doi: 10.1002/ijc.2910040108. [DOI] [PubMed] [Google Scholar]
  4. Smith D. B., Fox B. W., Thatcher N., Steward W. P., Scarffe J. H., Wagstaff J., Vezin R., Crowther D. Phase I clinical trial of methylene dimethane sulfonate. Cancer Treat Rep. 1987 Sep;71(9):817–820. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES